Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Maviret
Maviret 100 mg/40 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8–9
HOS-139039 · Präparat HOS-098268
8
Lovastatin ↑ lovastatin ↔ 1.70 -- Co-administration
10 mg once daily (1.40, is not
2.06) recommended. If
(Inhibition of ↑ lovastatin 5.73 4.10 -- used, lovastatin
OATP1B1/3, P- acid (4.65, 7.07) (3.45, should not exceed
gp, BCRP) 4.87) a dose of 20
mg/day and
patients should be
monitored.
Pravastatin ↑ pravastatin 2.23 2.30 -- Caution is
10 mg once daily (1.87, 2.65) (1.91, recommended.
2.76) Pravastatin dose
(Inhibition of should not exceed
OATP1B1/3) 20 mg per day
Rosuvastatin ↑ 5.62 2.15 -- and rosuvastatin
5 mg once daily rosuvastatin (4.80, 6.59) (1.88, dose should not
2.46) exceed 5 mg per
(Inhibition of day.
OATP1B1/3,
BCRP)
Fluvastatin, Not studied. Interactions with
Pitavastatin Expected: ↑ fluvastatin and ↑ pitavastatin fluvastatin and
pitavastatin are
likely and caution
is recommended
during the
combination. A
low dose of the
statin is
recommended at
the initiation of
the DAA
treatment.
IMMUNOSUPPRESSANTS
Ciclosporin ↑ glecaprevirc 1.30 1.37 1.34 Maviret is not
100 mg single (0.95, 1.78) (1.13, (1.12, 1.60) recommended for
dose 1.66) use in patients
↑ pibrentasvir ↔ ↔ 1.26 requiring stable
(1.15, 1.37) ciclosporin doses
Ciclosporin ↑ glecaprevir 4.51 5.08 -- > 100 mg per day.
400 mg single (3.63, 6.05) (4.11, If the combination
dose 6.29) is unavoidable,
↑ pibrentasvir ↔ 1.93 -- use can be
(1.78, considered if the
2.09) benefit outweighs
the risk with a
close clinical
monitoring.
Tacrolimus ↑ tacrolimus 1.50 1.45 -- The combination
1 mg single dose (1.24, 1.82) (1.24, of Maviret with
1.70) tacrolimus should
(CYP3A4 and P- ↔ ↔ ↔ ↔ be used with
gp inhibition) glecaprevir caution. Increase
↔ ↔ ↔ ↔ of tacrolimus
pibrentasvir exposure is
expected.
Therefore, a
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) tacrolimus (HOS-085202) pravastatin (HOS-086306) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-15T12:56:00Z · SHA-256 225c0ba8f2354e64e1131849dc7b6e23a86b099b858b5f9e8bda200a3bdf07cd · Passage 367b753680457b545e8392989af21731cbb002f8b6bc1081e4d022c9c01efc84 · Zeichen 15500–20605 im Abschnitt
Wechselwirkungen · Maviret
Maviret 50 mg/20 mg coated granules in sachet · Abschnitt 4.5 · PDF-Seite 34–35
HOS-139093 · Präparat HOS-098268
34
HCV-ANTIVIRAL AGENTS
Sofosbuvir ↑ sofosbuvir 1.66 2.25 -- No dose adjustment
400 mg single dose (1.23, 2.22) (1.86, 2.72) is required.
↑ GS- ↔ ↔ 1.85
(P-gp/BCRP 331007 (1.67, 2.04)
inhibition) ↔ ↔ ↔ ↔
glecaprevir
↔ ↔ ↔ ↔
pibrentasvir
HMG-COA REDUCTASE INHIBITORS
Atorvastatin ↑ 22.0 8.28 -- Co-administration
10 mg once daily atorvastatin (16.4, 29.5) (6.06, 11.3) with atorvastatin and
simvastatin is
(Inhibition of contraindicated (see
OATP1B1/3, P-gp, section 4.3).
BCRP, CYP3A)
Simvastatin ↑ 1.99 2.32 --
5 mg once daily simvastatin (1.60, 2.48) (1.93, 2.79)
↑ 10.7 4.48 --
(Inhibition of simvastatin (7.88, 14.6) (3.11, 6.46)
OATP1B1/3, P-gp, acid
BCRP)
Lovastatin ↑ lovastatin ↔ 1.70 -- Co-administration is
10 mg once daily (1.40, 2.06) not recommended. If
↑ lovastatin 5.73 4.10 -- used, lovastatin
(Inhibition of acid (4.65, 7.07) (3.45, 4.87) should not exceed a
OATP1B1/3, P-gp, dose of 20 mg/day
BCRP) and patients should
be monitored.
Pravastatin ↑ pravastatin 2.23 2.30 -- Caution is
10 mg once daily (1.87, 2.65) (1.91, 2.76) recommended.
Pravastatin dose
(Inhibition of should not exceed
OATP1B1/3) 20 mg per day and
Rosuvastatin ↑ 5.62 2.15 -- rosuvastatin dose
5 mg once daily rosuvastatin (4.80, 6.59) (1.88, 2.46) should not exceed
5 mg per day.
(Inhibition of
OATP1B1/3,
BCRP)
Fluvastatin, Not studied. Interactions with
Pitavastatin Expected: ↑ fluvastatin and ↑ pitavastatin fluvastatin and
pitavastatin are
likely and caution is
recommended
during the
combination. A low
dose of the statin is
recommended at the
initiation of the
DAA treatment.
IMMUNOSUPPRESSANTS
Ciclosporin ↑ 1.30 1.37 1.34 Maviret is not
100 mg single dose glecaprevirc (0.95, 1.78) (1.13, 1.66) (1.12, 1.60) recommended for
↑ ↔ ↔ 1.26 use in patients
pibrentasvir (1.15, 1.37) requiring stable
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sofosbuvir (HOS-108928) lovastatin (HOS-086157) atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) pravastatin (HOS-086306) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-15T12:56:00Z · SHA-256 225c0ba8f2354e64e1131849dc7b6e23a86b099b858b5f9e8bda200a3bdf07cd · Passage 07a1b621c990667394265e7af7d190b4e25e101150b99a5276f832859a7084c4 · Zeichen 12395–16855 im Abschnitt
Wechselwirkungen · Prevymis
PREVYMIS 240 mg film-coated tablets PREVYMIS 480 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11–12
HOS-139814 · Präparat HOS-098408
11
Concomitant Effect on concentration† Recommendations concerning co-
medicinal product mean ratio (90% confidence administration with letermovir
interval) for AUC, Cmax
(likely mechanism of action)
fluvastatin, Interaction not studied. Letermovir may increase statin plasma
pravastatin Expected: concentrations.
↑ HMG-CoA reductase
inhibitors When letermovir is co-administered with
these statins, a statin dose reduction may
(OATP1B1/3 and/or BCRP be necessary#. Statin-associated adverse
inhibition) events such as myopathy should be closely
monitored.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fluvastatin (HOS-086305) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-12T02:00:00Z · SHA-256 db4998a6cb590006789107af9f09c4196d815ed441a57d076042c2223b8d34a9 · Passage fbd096296e0ef8dbf3ba506de8177332b3b72b9199bff496b63c320c037f340d · Zeichen 20423–21335 im Abschnitt
Wechselwirkungen · Prevymis
PREVYMIS 240 mg film-coated tablets PREVYMIS 480 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-139815 · Präparat HOS-098408
When letermovir is co-administered with
cyclosporine, pravastatin is not
recommended while for fluvastatin, a dose
reduction may be necessary#. Statin-
associated adverse events such as
myopathy should be closely monitored.
Immunosuppressants
cyclosporine ↑ cyclosporine If letermovir is co-administered with
(50 mg single dose)/ AUC 1.66 (1.51, 1.82) cyclosporine, the dose of letermovir
letermovir (240 mg Cmax 1.08 (0.97, 1.19) should be decreased to 240 mg once daily
daily) (CYP3A inhibition) in adults (see sections 4.2 and 5.1) and
paediatric patients weighing at least 30 kg
cyclosporine ↑ letermovir (see section 4.2). If oral letermovir is co-
(200 mg single AUC 2.11 (1.97, 2.26) administered with cyclosporine in
dose)/ letermovir Cmax 1.48 (1.33, 1.65) paediatric patients weighing less than
(240 mg daily) 30 kg, the dose should be decreased (see
(OATP1B1/3 inhibition) section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fluvastatin (HOS-086305) cyclosporine (HOS-084512) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-12T02:00:00Z · SHA-256 db4998a6cb590006789107af9f09c4196d815ed441a57d076042c2223b8d34a9 · Passage fef40202fa97b78ae3de0e45954a3481ccc7e5ac9853dbfd409facfbd0884701 · Zeichen 21390–22801 im Abschnitt
Wechselwirkungen · Prevymis
PREVYMIS 240 mg concentrate for solution for infusion PREVYMIS 480 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 44
HOS-139882 · Präparat HOS-098408
(CYP3A, OATP1B1/3 When letermovir is co-administered with
inhibition) cyclosporine, use of these statins is
contraindicated.
fluvastatin, Interaction not studied. Letermovir may increase statin plasma
pravastatin Expected: concentrations.
↑ HMG-CoA reductase
inhibitors When letermovir is co-administered with
these statins, a statin dose reduction may
(OATP1B1/3 and/or BCRP be necessary#. Statin-associated adverse
inhibition) events such as myopathy should be closely
monitored.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fluvastatin (HOS-086305) cyclosporine (HOS-084512) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-12T02:00:00Z · SHA-256 db4998a6cb590006789107af9f09c4196d815ed441a57d076042c2223b8d34a9 · Passage 633575ba1b093129ec0678cd3f6e70ed8096b24f5ba0d931967295c273687e63 · Zeichen 20429–21344 im Abschnitt
Wechselwirkungen · Prevymis
PREVYMIS 240 mg concentrate for solution for infusion PREVYMIS 480 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 44
HOS-139883 · Präparat HOS-098408
When letermovir is co-administered with
cyclosporine, pravastatin is not
recommended while for fluvastatin, a dose
reduction may be necessary#. Statin-
associated adverse events such as
myopathy should be closely monitored.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fluvastatin (HOS-086305) cyclosporine (HOS-084512) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-12T02:00:00Z · SHA-256 db4998a6cb590006789107af9f09c4196d815ed441a57d076042c2223b8d34a9 · Passage 1dfbcbdfc5f00c803fb0f395a518021c77f1123a783c11616b11521a29a4943b · Zeichen 21403–21911 im Abschnitt
Wechselwirkungen · Prevymis
PREVYMIS 20 mg granules in sachet PREVYMIS 120 mg granules in sachet · Abschnitt 4.5 · PDF-Seite 77–78
HOS-139947 · Präparat HOS-098408
77
Concomitant Effect on concentration† Recommendations concerning co-
medicinal product mean ratio (90% confidence administration with letermovir
interval) for AUC, Cmax
(likely mechanism of action)
fluvastatin, Interaction not studied. Letermovir may increase statin plasma
pravastatin Expected: concentrations.
↑ HMG-CoA reductase
inhibitors When letermovir is co-administered with
these statins, a statin dose reduction may
(OATP1B1/3 and/or BCRP be necessary#. Statin-associated adverse
inhibition) events such as myopathy should be closely
monitored.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fluvastatin (HOS-086305) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-12T02:00:00Z · SHA-256 db4998a6cb590006789107af9f09c4196d815ed441a57d076042c2223b8d34a9 · Passage 8179db966700b3ab8a143b0dc56c2e032bed07d1cef19cb7754f518910f580a5 · Zeichen 20430–21342 im Abschnitt
Wechselwirkungen · Prevymis
PREVYMIS 20 mg granules in sachet PREVYMIS 120 mg granules in sachet · Abschnitt 4.5 · PDF-Seite 78
HOS-139948 · Präparat HOS-098408
When letermovir is co-administered with
cyclosporine, pravastatin is not
recommended while for fluvastatin, a dose
reduction may be necessary#. Statin-
associated adverse events such as
myopathy should be closely monitored.
Immunosuppressants
cyclosporine ↑ cyclosporine If letermovir is co-administered with
(50 mg single dose)/ AUC 1.66 (1.51, 1.82) cyclosporine, the dose of letermovir
letermovir (240 mg Cmax 1.08 (0.97, 1.19) should be decreased to 240 mg once daily
daily) (CYP3A inhibition) in adults (see sections 4.2 and 5.1) and
paediatric patients weighing at least 30 kg
cyclosporine ↑ letermovir (see section 4.2). If oral letermovir is co-
(200 mg single AUC 2.11 (1.97, 2.26) administered with cyclosporine in
dose)/ letermovir Cmax 1.48 (1.33, 1.65) paediatric patients weighing less than
(240 mg daily) 30 kg, the dose should be decreased (see
(OATP1B1/3 inhibition) section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fluvastatin (HOS-086305) cyclosporine (HOS-084512) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-12T02:00:00Z · SHA-256 db4998a6cb590006789107af9f09c4196d815ed441a57d076042c2223b8d34a9 · Passage fef40202fa97b78ae3de0e45954a3481ccc7e5ac9853dbfd409facfbd0884701 · Zeichen 21397–22808 im Abschnitt
Wechselwirkungen · Nubeqa
NUBEQA 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-142079 · Präparat HOS-098752
BCRP, OATP1B1 and OATP1B3 substrates
Darolutamide is an inhibitor of breast cancer resistance protein (BCRP) and Organic Anion
Transporting Polypeptides (OATP) 1B1 and 1B3.
Co-administration of rosuvastatin should be avoided unless there is no therapeutic alternative.
Selection of an alternative concomitant medicinal product with less potential to inhibit BCRP,
OATP1B1 and OATP1B3 should be considered.
Administration of darolutamide (600 mg twice daily for 5 days) prior to co-administration of a single
dose of rosuvastatin (5 mg) together with food resulted in approximately 5-fold increase in mean
exposure (AUC) and Cmax of rosuvastatin.
Co-administration of darolutamide with other BCRP substrates should be avoided where possible.
Co-administration of darolutamide may increase the plasma concentrations of other concomitant
BCRP, OATP1B1 and OATP1B3 substrates (e.g. methotrexate, sulfasalazine, fluvastatin, atorvastatin,
pitavastatin). Therefore, it is recommended to monitor patients for adverse reactions of BCRP,
OATP1B1 and OATP1B3 substrates. In addition, the related recommendation in the product
information of these substrates should be followed when co-administered with darolutamide.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfasalazine (HOS-089673) atorvastatin (HOS-086304) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) methotrexate (HOS-087522) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-21T11:00:00Z · SHA-256 da13d7ad15d93e78a0008f5eb25e09dc0942552321540cdc62987578c964dccb · Passage b407bc81061cc78c3ae3bac2be182cc0a238ef1a0dedf2d5aad3dc3fec4814ec · Zeichen 2356–3562 im Abschnitt
Wechselwirkungen · Hepcludex
HEPCLUDEX 2 mg powder for solution for injection · Abschnitt 4.5 · PDF-Seite 4–5
HOS-142395 · Präparat HOS-098824
4
As a precautionary measure, close clinical monitoring is warranted when NTCP substrates (e.g.
estrone-3-sulfate, fluvastatin, atorvastatin, pitavastatin, pravastatin, rosuvastatin, and thyroid
hormones) are co-administered with bulevirtide. When possible, co-administration of these substrates
should be avoided.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atorvastatin (HOS-086304) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) pravastatin (HOS-086306) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-31T10:15:00Z · SHA-256 56ea5f48399773f9051c5a5cc519d740db7ee3cdff519ad40c96b180c39a4a0f · Passage 5bc00e5853559726857dc88ed0e9146e50b0f5615b01993b4d440cf65424c81d · Zeichen 346–661 im Abschnitt
Wechselwirkungen · Nilemdo
Nilemdo 180 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-143217 · Präparat HOS-098954
Transporter-mediated drug interactions
Bempedoic acid and its glucuronide weakly inhibit OATP1B1 and OATP1B3 at clinically relevant
concentrations. Coadministration of bempedoic acid with medicinal products that are substrates of
OATP1B1 or OATP1B3 (i.e., bosentan, fimasartan, asunaprevir, glecaprevir, grazoprevir,
voxilaprevir, and statins such as atorvastatin, pravastatin, fluvastatin, pitavastatin, rosuvastatin, and
simvastatin [see section 4.4]) may result in increased plasma concentrations of these medicinal
products.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atorvastatin (HOS-086304) asunaprevir (HOS-143218) simvastatin (HOS-086158) rosuvastatin (HOS-086307) glecaprevir (HOS-086297) fluvastatin (HOS-086305) voxilaprevir (HOS-108930) grazoprevir (HOS-108815) bosentan (HOS-086291) pravastatin (HOS-086306) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-27T17:50:00Z · SHA-256 e22c45bda49313040ac4a284f068b61ba66ef21d794753c9c1627e320bff57f6 · Passage e3cde46d64bee9856eeb02defdf2dd1f019be752e72262dfa78d7864a952b079 · Zeichen 1595–2123 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.